Search Results 9581-9590 of 42558 for oral
Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...
If your examination and test results can't confirm milk allergy, a healthcare professional might administer an oral challenge. In this test, you are fed ...
Oral gonadotropin-releasing hormone antagonists for the treatment of uterine leiomyomas. Obstetrics & Gynecology. 2023; doi:10.1097/AOG.0000000000005145 ...
Participants who are able to switch to low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) prior to date of registration (and plan to ...
r, Oral and throat cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Salivary gland tumor, Soft palate cancer, Nasal and paranasal tumors ...
... Oral and throat cancer, Head and neck cancer, Skin cancer, Oropharyngeal cancer, Mouth cancer, Thyroid cancer, Melanoma, Squamous cell carcinoma of the skin ...
... Oral and throat cancer, Salivary gland cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Melanoma, Tonsil cancer, Skin cancer, Squamous cell ...
... oral therapy (10% of patients in the study were also taking ezetimibe). The median LDL cholesterol was 105 mg/dL in both groups. At the termination of the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.